Related Experiment Video

Updated: Aug 14, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Modified p27 Kip1 is efficient in suppressing HER2-mediated tumorigenicity

Heng-Yin Yang1, Huiling Yang, Ruiying Zhao

  • 1Department of Molecular and Cellular Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Journal of Cellular Biochemistry
|December 21, 2005
PubMed

Insights

Modified p27 proteins targeting HER2 signaling inhibit cancer cell growth and tumor volume. These engineered proteins offer a novel therapeutic strategy for HER2-overexpressing cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • The cyclin-dependent kinase (CDK) inhibitor p27 Kip1 is a tumor suppressor frequently downregulated in cancers.
  • HER2, a receptor tyrosine kinase oncogene, promotes cancer cell growth and transformation by enhancing p27 Kip1 degradation.
  • p27 Kip1 degradation is mediated by ubiquitination, influenced by JAB1 binding and Thr187 phosphorylation.

Purpose of the Study:

  • To develop novel anticancer agents by modifying p27 Kip1 to resist HER2-mediated degradation.
  • To evaluate the efficacy of modified p27 Kip1 proteins in inhibiting HER2-overexpressing cancer cells and tumors.

Main Methods:

  • Generation of modified p27 Kip1 proteins with mutations at Thr187 (p27 T187A) or deletion of the JAB1 binding domain (p27 DeltaJAB).
  • Utilized a tetracycline-regulated gene expression system to control the delivery of modified p27 Kip1 genes.
  • Assessed the impact of modified p27 Kip1 on HER2-activated cell growth, CDK2 activity, proliferation, and transformation in vitro.
  • Evaluated tumor volume reduction in a HER2-overexpressing tumor model in vivo.

Main Results:

  • Engineered p27 T187A and p27 T187A DeltaJAB proteins effectively inhibited HER2-driven cell growth, CDK2 activity, proliferation, and transformation.
  • The modified protein p27 T187ADeltaJAB significantly reduced tumor volume in a HER2-overexpressing tumor model.
  • These findings highlight the therapeutic potential of stabilized p27 Kip1 variants.

Conclusions:

  • Modified p27 Kip1 proteins, resistant to degradation, can serve as effective anticancer agents against HER2-overexpressing cancers.
  • Targeting p27 Kip1 stability presents a promising therapeutic strategy for HER2-driven malignancies.
  • This study demonstrates the clinical applicability of engineered p27 Kip1 proteins in cancer therapy.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...